Cover Image
市場調查報告書

肌肉萎縮性側索硬化症 : 開發中產品分析

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 232799
出版日期 內容資訊 英文 487 Pages
訂單完成後即時交付
價格
Back to Top
肌肉萎縮性側索硬化症 : 開發中產品分析 Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018
出版日期: 2018年04月17日 內容資訊: 英文 487 Pages
簡介

肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)是運動神經原·系統最常見的退化性疾病。這個障礙是由其病態生理學原因命名,為上、下運動神經元的退化,而臨床方面ALS會表現同側肢體的下運動神經元徵象(如無力、萎縮和肌束抽搐)及上運動神經元徵象(如肌腱反射上升、霍夫曼徵象(Hoffmann signs)、巴賓斯基反射(Babinski signs)或肌躍症)。症狀有呼吸困難、吞嚥障礙、頭部肌肉無力下垂、肌肉痙攣、緩慢或異常的說話方式之會話障礙、變聲、聲音嘶啞、體重減輕等。

本報告提供肌肉萎縮性側索硬化症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您夾雜了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

肌肉萎縮性側索硬化症 概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10324IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate.

Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 4, 24, 16, 2, 78, 21 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 34 and 9 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 3
  • Amyotrophic Lateral Sclerosis - Overview 4
  • Amyotrophic Lateral Sclerosis - Therapeutics Development 5
  • Amyotrophic Lateral Sclerosis - Therapeutics Assessment 29
  • Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 45
  • Amyotrophic Lateral Sclerosis - Drug Profiles 81
  • Amyotrophic Lateral Sclerosis - Dormant Projects 443
  • Amyotrophic Lateral Sclerosis - Discontinued Products 453
  • Amyotrophic Lateral Sclerosis - Product Development Milestones 455
  • Appendix 465

List of Tables

  • Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2018 28
  • Number of Products under Development by Companies, H1 2018 30
  • Number of Products under Development by Universities/Institutes, H1 2018 37
  • Products under Development by Companies, H1 2018 39
  • Products under Development by Universities/Institutes, H1 2018 48
  • Number of Products by Stage and Target, H1 2018 53
  • Number of Products by Stage and Mechanism of Action, H1 2018 59
  • Number of Products by Stage and Route of Administration, H1 2018 65
  • Number of Products by Stage and Molecule Type, H1 2018 67
  • Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H1 2018 68
  • Amyotrophic Lateral Sclerosis - Pipeline by Acceleron Pharma Inc, H1 2018 68
  • Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp, H1 2018 69
  • Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp, H1 2018 69
  • Amyotrophic Lateral Sclerosis - Pipeline by Apogenix AG, H1 2018 70
  • Amyotrophic Lateral Sclerosis - Pipeline by Apotex Inc, H1 2018 70
  • Amyotrophic Lateral Sclerosis - Pipeline by Aquestive Therapeutics, H1 2018 70
  • Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen Inc, H1 2018 71
  • Amyotrophic Lateral Sclerosis - Pipeline by Avanir Pharmaceuticals Inc, H1 2018 71
  • Amyotrophic Lateral Sclerosis - Pipeline by AveXis Inc, H1 2018 71
  • Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H1 2018 72
  • Amyotrophic Lateral Sclerosis - Pipeline by BioElectron Technology Corp, H1 2018 72
  • Amyotrophic Lateral Sclerosis - Pipeline by Biogen Inc, H1 2018 73
  • Amyotrophic Lateral Sclerosis - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018 73
  • Amyotrophic Lateral Sclerosis - Pipeline by BioHealthonomics Inc, H1 2018 74
  • Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2018 74
  • Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H1 2018 74
  • Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals Inc, H1 2018 75
  • Amyotrophic Lateral Sclerosis - Pipeline by CerSci Therapeutics Inc, H1 2018 75
  • Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Ltd, H1 2018 75
  • Amyotrophic Lateral Sclerosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018 76
  • Amyotrophic Lateral Sclerosis - Pipeline by Corcept Therapeutics Inc, H1 2018 76
  • Amyotrophic Lateral Sclerosis - Pipeline by Corestem Inc, H1 2018 77
  • Amyotrophic Lateral Sclerosis - Pipeline by CSPC NBP Pharmaceutical Co Ltd, H1 2018 77
  • Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics Inc, H1 2018 78
  • Amyotrophic Lateral Sclerosis - Pipeline by Daval International Ltd, H1 2018 78
  • Amyotrophic Lateral Sclerosis - Pipeline by Denali Therapeutics Inc, H1 2018 78
  • Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co Ltd, H1 2018 79
  • Amyotrophic Lateral Sclerosis - Pipeline by Ensemble Therapeutics Corp, H1 2018 79
  • Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H1 2018 80
  • Amyotrophic Lateral Sclerosis - Pipeline by Gemac SA, H1 2018 80
  • Amyotrophic Lateral Sclerosis - Pipeline by Genentech Inc, H1 2018 81
  • Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H1 2018 81
  • Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H1 2018 81
  • Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex SA, H1 2018 82
  • Amyotrophic Lateral Sclerosis - Pipeline by Gilead Sciences Inc, H1 2018 82
  • Amyotrophic Lateral Sclerosis - Pipeline by Glialogix Inc, H1 2018 83
  • Amyotrophic Lateral Sclerosis - Pipeline by Grifols SA, H1 2018 83
  • Amyotrophic Lateral Sclerosis - Pipeline by Hemostemix Inc, H1 2018 83
  • Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H1 2018 84
  • Amyotrophic Lateral Sclerosis - Pipeline by Implicit Bioscience Ltd, H1 2018 84
  • Amyotrophic Lateral Sclerosis - Pipeline by InFlectis BioScience, H1 2018 85
  • Amyotrophic Lateral Sclerosis - Pipeline by Ionis Pharmaceuticals Inc, H1 2018 85
  • Amyotrophic Lateral Sclerosis - Pipeline by Italfarmaco SpA, H1 2018 86
  • Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018 86
  • Amyotrophic Lateral Sclerosis - Pipeline by K-Pax Pharmaceuticals Inc, H1 2018 87
  • Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd, H1 2018 87
  • Amyotrophic Lateral Sclerosis - Pipeline by KineMed Inc, H1 2018 87
  • Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma Inc, H1 2018 88
  • Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018 88
  • Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018 89
  • Amyotrophic Lateral Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2018 89
  • Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corp, H1 2018 89
  • Amyotrophic Lateral Sclerosis - Pipeline by M3 Biotechnology Inc, H1 2018 90
  • Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H1 2018 90
  • Amyotrophic Lateral Sclerosis - Pipeline by MallInckrodt Plc, H1 2018 91
  • Amyotrophic Lateral Sclerosis - Pipeline by MedDay SA, H1 2018 91
  • Amyotrophic Lateral Sclerosis - Pipeline by MimeTech Srl, H1 2018 91
  • Amyotrophic Lateral Sclerosis - Pipeline by Miragen Therapeutics Inc, H1 2018 92
  • Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018 92
  • Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem Inc, H1 2018 93
  • Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2018 93
  • Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H1 2018 93
  • Amyotrophic Lateral Sclerosis - Pipeline by Neurofx Inc, H1 2018 94
  • Amyotrophic Lateral Sclerosis - Pipeline by NeuroSense Therapeutics Ltd, H1 2018 94

List of Figures

  • Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2018 28
  • Number of Products under Development by Companies, H1 2018 29
  • Number of Products under Development by Universities/Institutes, H1 2018 37
  • Number of Products by Top 10 Targets, H1 2018 52
  • Number of Products by Stage and Top 10 Targets, H1 2018 52
  • Number of Products by Top 10 Mechanism of Actions, H1 2018 58
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 58
  • Number of Products by Routes of Administration, H1 2018 64
  • Number of Products by Stage and Routes of Administration, H1 2018 64
  • Number of Products by Top 10 Molecule Types, H1 2018 66
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018 66
Back to Top